

THE WELINK.CARE LABEL HAS BEEN AWARDED TO



DermaDetect

ON THE 30TH OF APRIL 2022

WITH THE VERY HIGH DISRUPTION SCORE OF 81 %



A handwritten signature in black ink, appearing to read "Thierry Vermeeren", written over a horizontal line.

Dr. Thierry Vermeeren, CEO

The WeLink.Care label uses a composite index scoring the disruption value of a digital solution use case in the daily health practice. Our expert team has reviewed the preselected digital solution with a set of 35 points of measure, based on interviews, documents research and analysis.

DERMADETECT RECEIVES THE WELINK.CARE LABEL

Introduction

DermaDetect has been honored with the prestigious WeLink.Care Label, a recognition that reflects its significant contribution to advancing digital healthcare. This accolade underscores DermaDetect's commitment to enhancing dermatological care through innovation, accessibility, and integration, cementing its place among the most impactful eHealth solutions globally.

About the WeLink.Care Label

The WeLink.Care Label was introduced to identify, evaluate, and promote digital health solutions that demonstrate exceptional innovation and measurable impact on healthcare practices. Established during the global COVID-19 pandemic, it initially focused on curating a catalog of solutions to address immediate healthcare needs. Its success has since extended its scope to cover a broad spectrum of eHealth domains.

Using a comprehensive and scientifically rigorous methodology, the WeLink.Care Label evaluates solutions across multiple dimensions, including technological innovation, practice transformation, and user experience for both patients and healthcare professionals. Solutions that receive the label have proven their capacity to enhance healthcare efficiency and quality while aligning with stringent standards of reliability and usability. This recognition not only validates the value of a solution but also promotes its integration into healthcare ecosystems worldwide.

The Evaluation Process

The WeLink.Care evaluation process employs a robust and transparent framework, designed to thoroughly assess the disruption potential and practical utility of healthcare innovations. The process is centered around five critical dimensions: Business Model, Solution Maturity, Change of Practices, and User Experience for both professionals and patients. The evaluation begins with an in-depth review of the solution's design, functionality, and implementation strategies. Using a proprietary scoring system, certified experts analyze over 50 specific criteria, including scientific validation, user engagement, and cost-effectiveness. Each criterion is tailored to reflect the nuances of healthcare practice and technology integration.

The process incorporates feedback from key stakeholders, including developers, users, and healthcare providers. Detailed interviews and surveys provide qualitative and quantitative data, enabling evaluators to understand the real-world implications of the solution. This ensures the evaluation reflects the experiences of those directly impacted by the solution's deployment. The evaluated solution is benchmarked against global standards and similar innovations in the field. This comparative analysis highlights areas of competitive advantage while identifying potential gaps. The goal is to ensure that solutions not only meet but exceed industry norms for innovation and impact.

Upon completing the evaluation, results are compiled into a Scorecard and, if applicable, a detailed Impact Study. The Scorecard presents a concise, number-based assessment with context to guide stakeholders in understanding the solution's strengths and areas for improvement. The Impact Study provides a deeper dive into the findings, offering actionable recommendations and insights for optimization. This rigorous process ensures that every solution awarded the WeLink.Care Label is not only innovative but also aligned with the dynamic needs of healthcare systems and patient populations.

DERMADETECT

Introduction to the company

Founded in 2017 in Rehovot, Israel, DermaDetect emerged as a response to the global need for accessible, efficient, and accurate dermatological care. Leveraging the power of artificial intelligence, the company provides innovative solutions that address challenges in dermatology, including long waiting times, geographic barriers, and the growing demand for specialist consultations. Led by a team of experienced professionals in medicine, technology, and business, DermaDetect has quickly established itself as a leader in digital dermatology. DermaDetect's commitment to innovation and collaboration is evident in its partnerships with leading healthcare organizations, including Maccabi Health Services, which serves 2.4 million patients. The company's FDA- and CE-cleared platform reflects a dedication to quality and regulatory standards, further validated by support from eHealth Ventures and other prominent investors. Through a focus on patient-centric care and seamless integration into clinical workflows, DermaDetect exemplifies how technology can transform traditional healthcare paradigms.

The Solution

DermaDetect offers an AI-powered platform designed to enhance the diagnosis, treatment, and management of dermatological conditions. By simulating the analytical process of dermatologists, the solution enables healthcare providers to deliver accurate, timely care remotely. Its ability to integrate patient-provided data, including images and symptom details, allows for a comprehensive evaluation that aligns with clinical protocols. The platform supports asynchronous teledermatology, enabling physicians to review cases at their convenience while maintaining high diagnostic accuracy. Patients benefit from a user-friendly mobile app that simplifies the process of submitting images and symptoms, while clinicians gain access to advanced diagnostic tools that streamline decision-making. This holistic approach ensures that patients receive personalized care without the need for unnecessary clinic visits.

Features and Benefits

DermaDetect's platform combines cutting-edge AI with practical features to deliver exceptional value to patients, providers, and healthcare systems. The solution's key features include advanced image analysis, which leverages deep learning and computer vision to evaluate skin conditions with up to 98% accuracy for common dermatological conditions. Its comprehensive database supports differential diagnosis for over 300 skin diseases, empowering clinicians with reliable insights. The platform also benefits healthcare systems by optimizing workflows, reducing administrative burdens, and increasing patient satisfaction. Patients enjoy enhanced privacy, minimized travel, and faster diagnoses, with 80% of cases resolved remotely. For healthcare professionals, DermaDetect offers a secure web interface with tools for patient management, clinical decision support, and seamless integration into existing electronic health records.

Compliance and Future Outlook

DermaDetect demonstrates a strong commitment to compliance, having achieved FDA and CE certifications for its teledermatology platform. These credentials highlight its adherence to global standards for medical device safety and efficacy. The platform's secure architecture ensures patient data protection, meeting stringent privacy regulations. Looking ahead, DermaDetect plans to expand its capabilities with features such as triage for critical conditions, enhanced clinical decision support, and data-driven treatment recommendations. These advancements position DermaDetect to remain at the forefront of digital dermatology, driving improved outcomes and accessibility in skin health worldwide.

DISRUPTION SCORE


The disruption score highlights DermaDetect's strong financial foundation, bolstered by investor support in 2022, and its advanced commercialization stage. By facilitating rapid access to patient data, swift diagnosis, and tailored dermatological treatments, the platform significantly improves patient care. While the solution excels as a diagnostic aid with a comprehensive database and close patient follow-up, the lack of extensive scientific publications on clinical effectiveness remains an area for improvement to enhance its validation and impact.

BUSINESS PERFORMANCE




|~ good ~|

CHANGE OF PRACTICES




|~ very significant ~|

DISRUPTION POTENTIAL



|~ very high ~|

SOLUTION MATURITY



|~ high ~|

USER EXPERIENCE



|~ very good ~|

BUSINESS MODEL

DermaDetect's business model demonstrates strong financial performance, securing €2.1M in 2022 and a cumulative €3.1M across prior funding rounds. Currently serving Israel, the company partners with Maccabi Health Services, reaching 2.4M patients, and is utilized by pediatricians at Yeled Shalom Clinic. With plans to expand internationally, DermaDetect is targeting entry into the U.S. market, followed by Europe, showcasing its scalable vision and commitment to global accessibility in digital dermatology.

BUSINESS MODEL




|~ good ~|

COMMERCIAL READINESS LEVEL



|~ first sales ~|

BUSINESS PERFORMANCE



|~ good ~|

SOLUTION MATURITY

DermaDetect has reached the commercialization stage, offering a clinically robust teledermatology platform. Its development has been guided by expert input from a renowned dermatology professor and a leading pediatrician, ensuring medical relevance and precision. While the solution demonstrates strong practical utility, the limited availability of scientific publications validating its clinical effectiveness presents an opportunity to strengthen its evidence base and further establish its credibility in the global healthcare community.

CLINICAL TRIALS



|~ one published study ~|

PREMS & PROMS




|~ insufficient ~|

DESIGN APPROACH



|~ adequate ~|

SOLUTION MATURITY



|~ high ~|

TECHNOLOGY READINESS LEVEL




|~ product deployed ~|

CHANGE OF PRACTICES


DermaDetect significantly transforms dermatological practices by streamlining access to patient data, accelerating diagnosis, and facilitating tailored treatment recommendations. Its robust database supports over 300 dermatological conditions, equipping clinicians with comprehensive diagnostic tools. The platform enhances continuity of care by reducing consultation delays, offering timely and effective interventions. With CE marking and FDA certification, DermaDetect ensures compliance with global standards, driving improved efficiency and quality in dermatological care delivery.

PRACTICES MEASURE POINTS



| ~ 12 relevant measure points ~ |

CHANGE OF PRACTICES



| ~ very significant ~ |

USER EXPERIENCE : THE PROFESSIONAL AND PATIENT PERSPECTIVE

DermaDetect offers an intuitive user experience, streamlining dermatologists' workflows and supporting accurate, timely diagnoses through its robust database of over 300 conditions. Patients benefit from quick lesion assessments and close follow-ups, enhancing their care journey. The app is free, user-friendly, and adaptable to various healthcare systems, where consultation costs align with local frameworks. This accessibility empowers both patients and professionals, improving efficiency and satisfaction in dermatological care.




|~ very good ~|

PROFESSIONAL EXPERIENCE



PATIENT EXPERIENCE



|~ very good ~|

USER EXPERIENCE



|~ very good ~|

LINKS AND RESOURCES

<https://www.dermadetect.com/>

<https://label.welink.care/>

This report is based on the information provided by the scored company, input from various stakeholders, and the application of the WeLink.Care© methodology by OZConsulting. The findings, scores, and evaluations presented are intended solely for informational purposes and do not constitute a guarantee or endorsement of the quality, effectiveness, or commercial viability of the evaluated digital health solution.

The conclusions are drawn from the data available at the time of the study and may not reflect subsequent changes. OZConsulting assumes no responsibility for the accuracy or completeness of the information provided by the scored company or any third parties involved. Any reliance on this report is at the reader's own risk.

The content of this report is protected under copyright law. No part of this report may be reproduced, distributed, or used for commercial purposes without prior written permission from OZC. The WeLink.Care© methodology and scoring system are proprietary to OZConsulting.
